Pharmaceuticals Analysts discuss the anticipated adoption and use of Biogen (BIIB) and Sage Therapeutics’ (SAGE) Zuranolone, once it receives FDA approval, on an Analyst/Industry conference call to be held on July 7.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on BIIB:
- Biogen, Eisai’s Alzheimer’s Drug Scores Big With FDA’s Full Approval
- FDA Grants Traditional Approval for LEQEMBI® (lecanemab-irmb) for the Treatment of Alzheimer’s Disease
- Biogen, Eisai win full FDA approval for Alzheimer’s drug Leqembi
- FDA converts Biogen Alzheimer’s treatment to full approval
- Biogen trading halted, news pending